Alkermes (ALKS) Stock Forecast & Price Target

Compare

618 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$46.20

▲(32.61% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $46.20 with a high forecast of $58.00 and a low forecast of $37.00. The average price target represents a 32.61% change from the last price of $34.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","42":"$42","59":"$59","33.5":"$33.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,33.5,42,50.5,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.96,36.73230769230769,38.504615384615384,40.276923076923076,42.04923076923077,43.82153846153846,45.59384615384616,47.36615384615385,49.13846153846154,50.91076923076923,52.683076923076925,54.45538461538462,56.22769230769231,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.96,35.824615384615385,36.68923076923077,37.55384615384615,38.41846153846154,39.283076923076926,40.14769230769231,41.012307692307694,41.87692307692308,42.74153846153846,43.606153846153845,44.470769230769235,45.33538461538462,{"y":46.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.96,35.11692307692308,35.27384615384616,35.43076923076923,35.58769230769231,35.744615384615386,35.901538461538465,36.058461538461536,36.215384615384615,36.37230769230769,36.52923076923077,36.68615384615384,36.84307692307692,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.985,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$58.00

Average Price Target$46.20

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Akash Tewari

Jefferies

$58

Buy

66.48%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), Waters (NYSE: WAT) and Alkermes (NASDAQ: ALKS)

Uy Ear

Mizuho Securities

$45

Buy

29.16%

Upside

Reiterated

01/29/26

Mizuho Securities Keeps Their Buy Rating on Alkermes (ALKS)

David Amsellem

Piper Sandler

$45

Buy

29.16%

Upside

Reiterated

01/16/26

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Ami Fadia

Needham

$44

Buy

26.29%

Upside

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Delcath Systems (NASDAQ: DCTH)

Leonid Timashev

RBC Capital

$47

Buy

34.90%

Upside

Reiterated

01/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Alkermes (NASDAQ: ALKS) and Apellis Pharmaceuticals (NASDAQ: APLS)

Benjamin Burnett

Wells Fargo

$37

Buy

6.20%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (NASDAQ: BCRX), Wave Life Sciences (NASDAQ: WVE) and Alkermes (NASDAQ: ALKS)

Jason Gerberry

Bank of America Securities

Hold

―

Reiterated

12/08/25

Alkermes (ALKS) Gets a Hold from Bank of America Securities

Douglas Tsao

H.C. Wainwright

$46

Hold

32.03%

Upside

Reiterated

11/20/25

Cautious Optimism: Alkermes' Strategic Moves and Market Potential Amidst Investor Concerns

Joon Lee

Truist Financial

$50→$55

Buy

57.86%

Upside

Reiterated

11/17/25

Truist Financial Keeps Their Buy Rating on Alkermes (ALKS)

David Hoang

Deutsche Bank

$55→$45

Buy

29.16%

Upside

Reiterated

11/13/25

Alkermes (ALKS) Gets a Buy from Deutsche Bank

Joseph Thome

TD Cowen

$40

Buy

14.81%

Upside

Reiterated

11/12/25

Analysts Conflicted on These Healthcare Names: Alkermes (NASDAQ: ALKS), Xoma (NASDAQ: XOMA) and Novavax (NASDAQ: NVAX)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

11/12/25

Alkermes' Strong Position and Misinterpreted Data: Justifying a Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

43.51%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

20.55%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)

Marc Goodman

Leerink Partners

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Akash Tewari

Jefferies

$58

Buy

66.48%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), Waters (NYSE: WAT) and Alkermes (NASDAQ: ALKS)

Uy Ear

Mizuho Securities

$45

Buy

29.16%

Upside

Reiterated

01/29/26

Mizuho Securities Keeps Their Buy Rating on Alkermes (ALKS)

David Amsellem

Piper Sandler

$45

Buy

29.16%

Upside

Reiterated

01/16/26

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Ami Fadia

Needham

$44

Buy

26.29%

Upside

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Delcath Systems (NASDAQ: DCTH)

Leonid Timashev

RBC Capital

$47

Buy

34.90%

Upside

Reiterated

01/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Alkermes (NASDAQ: ALKS) and Apellis Pharmaceuticals (NASDAQ: APLS)

Benjamin Burnett

Wells Fargo

$37

Buy

6.20%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (NASDAQ: BCRX), Wave Life Sciences (NASDAQ: WVE) and Alkermes (NASDAQ: ALKS)

Jason Gerberry

Bank of America Securities

Hold

―

Reiterated

12/08/25

Alkermes (ALKS) Gets a Hold from Bank of America Securities

Douglas Tsao

H.C. Wainwright

$46

Hold

32.03%

Upside

Reiterated

11/20/25

Cautious Optimism: Alkermes' Strategic Moves and Market Potential Amidst Investor Concerns

Joon Lee

Truist Financial

$50→$55

Buy

57.86%

Upside

Reiterated

11/17/25

Truist Financial Keeps Their Buy Rating on Alkermes (ALKS)

David Hoang

Deutsche Bank

$55→$45

Buy

29.16%

Upside

Reiterated

11/13/25

Alkermes (ALKS) Gets a Buy from Deutsche Bank

Joseph Thome

TD Cowen

$40

Buy

14.81%

Upside

Reiterated

11/12/25

Analysts Conflicted on These Healthcare Names: Alkermes (NASDAQ: ALKS), Xoma (NASDAQ: XOMA) and Novavax (NASDAQ: NVAX)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

11/12/25

Alkermes' Strong Position and Misinterpreted Data: Justifying a Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

43.51%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

20.55%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)

Marc Goodman

Leerink Partners

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

3 Months

xxx

Success Rate

15/19 ratings generated profit

Average Return

+6.53%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +6.53% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

18/19 ratings generated profit

Average Return

+24.69%

reiterated a buy rating 3 months ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +24.69% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+31.73%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +31.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 52 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 46.20.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Currently, no earnings data available.

ALKS Sales Forecast

Currently, no sales data available.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes’s 12-month average price target is 46.20.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes has 32.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is Alkermes’s price target?

The average price target for Alkermes is 46.20. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $58.00 ,the lowest forecast is $37.00. The average price target represents 32.61% Increase from the current price of $34.84.

What do analysts say about Alkermes?

Alkermes’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Detailed List of Analyst Forecasts